Innealta Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Innealta Capital’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,025	Closed	-$65.3K	–	238
2024 Q2	$65.3K	Buy	+1,025	New	+$66.5K	0.02%	302

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Innealta Capital's ANIP Position: Q3 2024 in Review

Innealta Capital sold out of ANI Pharmaceuticals (ANIP) in Q3 2024, closing a stake of 1,025 shares — an estimated $65.3K sold.

Innealta Capital first reported a position in ANIP in Q2 2024 and held it in 1 quarter. The position peaked at $65.3K in Q2 2024. 208 funds tracked by Wall St. Rank hold ANIP as of Q3 2024.

Innealta Capital reported no remaining ANI Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 1,025 ANI Pharmaceuticals shares in Q3 2024, an estimated $65.3K.
Innealta Capital first reported a position in ANI Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Innealta Capital's ANI Pharmaceuticals position peaked at $65.3K in Q2 2024.
208 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.